We invest in bioscience to accelerate medical innovation.
At Ethical Bioscience Investments, our mission is to provide unique fixed income opportunities for qualified investors looking to invest across the global bioscience sector.
A member of bioscience enterprise The iQ Group Global, EBI investments are carefully vetted and validated by our scientific and investment committees, comprised of highly-qualified professionals experienced in the monetisation, corporatisation, commercialisation, risk profiles and value creation process of life science innovations. With our unique investment strategy, our experts carefully select and validate late-discovery or pre-clinical stage life science companies, with assets that have potential for significant value appreciation.
Bioscience is the DNA of tomorrow’s medicines.
With global healthcare under unprecedented pressure, innovation must accelerate like never before.
Population increase, rising life expectancy, urbanisation and the spread of infectious diseases demand a new frontier for bioscience innovation to ensure the right medicines are developed when the world needs them most.
At Ethical Bioscience Investments, we invest across the entire bioscience sector – from chemical, biologic, genetic pharmaceutical interventions, to advanced point of care diagnostics, medicine nanorobotics, all at the forefront of medical research.
Investment Philosophy
At Ethical Bioscience Investments, our scientific and investment committees only invest in companies with a clear competitive advantage.
Ethical Bioscience Investments holds a competitive advantage when reviewing investments within the bioscience sector.
The iQ Group Global is a unique enterprise that converges bioscience with investment banking and commercialization to accelerate innovation and bring new therapeutic interventions to the world. This gives Ethical Bioscience Investments the capability to make informed and educated investments, add value to investee companies, and mitigate downside risk for investors to positively impact the future of healthcare. Our investment doctrine stems from our validation trinity: Science, People, Financials.
Science: Our experts validate the scientific merit of the innovation and the viability of the proposed development plan.
People: We know that it takes great people to create and sustain great companies. In our due diligence, we seek proof that the leaders of the companies we invest in have the will, capabilities and capacity to do just that.
Financials: We select investments based on their financial and industry position, as well as market and economic conditions.
About The iQ Group Global
The iQ Group Global is an award-winning consortium of companies that finds, funds and develops innovative bioscience intellectual property from world-class academic institutions to create life-changing medical innovations.
The Biosensor Diagnostic Platform
The Biosensor platform is a small, organic strip that will put the power of accurate, timely diagnosis in the hands of patients and their primary health practitioners.
TEX Core Oncology Platform
A world first platform, TEX Core allows the creation of novel oncology compounds that can be delivered directly to tumor cells with minimal side effects.
